Antigenics, Inc. (Pennsylvania) engages in the development of pharmaceutical products for cancer treatment. The company is headquartered in Horsham, Pennsylvania and currently employs 29 full-time employees. The company went IPO on 2001-07-18. The firm is developing a series of checkpoint modulators (CPM) for the treatment of patients with cancer, infectious diseases, and other immune disorders; heat shock protein (HSP)-based vaccines, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Retrocyte Display (Retroviral B Lymphocyte Display) is an antibody discovery platform designed for the discovery and optimization of fully human and humanized monoclonal antibodies against an array of molecular targets. Its HSP-based vaccine platform includes its Prophage Series vaccine candidates for the treatment of cancer and its HerpV vaccine candidate for the treatment of genital herpes. Its pipeline of product candidates containing QS-21 Stimulon includes vaccines for infectious diseases, cancer types and Alzheimer's disease.
Follow-Up Questions
Antigenics Inc (ANTI)'in P/E oranı nedir?
Antigenics Inc 'in P/E oranı 0 'dir
Antigenics Inc 'in CEO'su kimdir?
DR. Geoffrey Cox 1997 'den beri şirketle birlikte olan Antigenics Inc 'in Chairman of the Board 'ıdır.
ANTI hissesinin fiyat performansı nasıl?
ANTI 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Antigenics Inc için ana iş temaları veya sektörler nelerdir?
Antigenics Inc N/A endüstrisine ait ve sektör N/A 'dir
Antigenics Inc 'in piyasa değerlemesi nedir?
Antigenics Inc 'in mevcut piyasa değerlemesi $0 'dir
